Clinical Trial Update: Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluated the safety of Talimogene laherparepvec injected into tumors alone and in combination with pembrolizumab in hepatocellular c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Imlygic (Talimogene laherparepvec)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Amgen | Conditions: Hepatocellular Carcinoma, Liver Metastases | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-30